Johnson & Johnson to reveal Q3 figures

Johnson & Johnson will report its third-quarter results on Tuesday 14 October. Traders are expecting revenue of $18.34 billion and earnings per share of $1.42.

Johnson's baby oil bottle
Source: Bloomberg

Johnson & Johnson is trading at $104.61. The share price is down 1.1% since the company revealed its second-quarter figures in July, when revenue increased 9.1% to $19.5 billion and EPS rose by 12.9% to $1.66, both exceeding analysts’ estimates.

The CEO Alex Gorsky stated the strong second quarter was attributable to the ‘success of new product launches’. Global pharmaceutical sales jumped 21% to $8.5 billion and this was partially due to the popularity of its new drug Olysio, which is used to treat hepatitis C. Revenues at the consumer division rose by 2.4% while the medical services unit eked out a 0.7% increase in sales. Mr Gorsky hinted at going on the acquisition trail to increase the company’s portfolio in the medical services field.

Equity analysts are very bullish on the stock. Out of the 29 recommendations, 15 are buys, 13 are holds and only one is a sell.

Over the past month the stock has been rangebound between $102-$106. The 200-day moving average of $99.25 is providing support while robust numbers could put the stock on a path to $110.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.